Japan Biotechno Pharma

Japan Biotechno Pharma is a clinical-stage biopharmaceutical company headquartered in Kobe, Japan, specializing in the development of new treatments for rare and intractable diseases through drug repositioning. The company's primary focus is on identifying existing drugs with established safety profiles and repurposing them for new therapeutic indications, thereby reducing development risks and timelines. Its lead candidate, JBP0171 (meclozine hydrochloride), is currently in Phase 2 clinical trials for achondroplasia, where it acts by inhibiting the overactive signaling of Fibroblast Growth Factor Receptor 3. Japan Biotechno Pharma also maintains a pipeline including JBP01 for dry eye syndrome and JBP02 for oncology, supported by collaborations with academic institutions like Nagoya University. The company leverages its location in the Kobe Biomedical Innovation Cluster to advance its clinical programs toward commercialization.